Trial result
Larotrectinib, TRK Inhibitor, Achieves 77% Response in Treatment-Naïve (First-Line) TRK Fusion Cancers
- Cancer type
- Solid Tumors
- Published in
- New in Oncology - May 29, 2025
In 101 patients across three trials including pediatric patients, larotrectinib, the TRK inhibitor, yielded a 77% overall response rate with median PFS of 61 months. Overall survival was not reached. Most treatment-related adverse events remained grade 1/2.
Take home
Great to see TRK inhibitors moving into front-line therapy, and giving another great reason to perform NGS on every patient with high risk cancer! 77% ORR for 61 mPFS - WOW! Can anyone say NEOADJUVANT…
Source: Read the original publication
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings